Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2593-2603

  Kleinberg, Lawrence ^a   Grossman, S A ^a   Piantadosi, S ^a   Pearlman, J ^a   Engelhard, H ^a   Lesser, G ^a   Ruffer, J ^a   Gerber, M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (3,5 DIMETHYLANILINO)CARBOXYL]METHYL]PHENOXY] 2 METHYLPROPRIONIC ACID; ANTINEOPLASTIC AGENT; EFAPROXIRAL; HEMOGLOBIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GLIOBLASTOMA; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; OXYGEN AFFINITY; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0032796232     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2593     Document Type: Article

References (44)

1. Teicher BA, Gulshan A, Emi Y, et al: RSR13: Effects on tumor oxygenation and response to therapy. Drug Dev Res 38:1-11, 1996
2. Teicher BA, Wong JS, Takeuchi H, et al: Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 42:24-30, 1998
3. Khandelwal SR, Lin PS, Hall CE, et al: Increased radiation response of FsaII fibrosarcomas in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity. Radiat Oncol Invest 4:51-59, 1996
4. Lesser GJ, Shaw EG, Lovelace JK, et al: Improved intratumoral oxygenation following RSR13 infusion in man: A case report. Proc Am Soc Clin Oncol 17:407a, 1998 (abstr 1659)
5. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29:427-431, 1994
6. Grossman SA, Brem H, Piantadosi S, et al: The NABTT CNS Consortium: Organization, objectives and progress. Cancer Control 5:107-114, 1998
7. Grossman SA, Fisher J, Piantadosi S: The NABTT glioblastoma database: An objective means to select novel agents for phase III testing. Proc Am Soc Clin Oncol 17:406a, 1998 (abstr 1565)
8. Randad RS, Mahran MA, Mehanna AS, et al: Allosteric modifiers of hemoglobin: I. Design, synthesis, testing and structure-allosteric activity relationships of novel hemoglobin oxygen affinity decreasing agents. J Med Chem 34:752-757, 1991
9. Abraham DJ, Wireko FC, Randad RS, et al: Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 31:9141-9149, 1992
10. Khandelwal SR, Randad RS, Lin P-S, et al: Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am J Physiol 34:1450-1453, 1993
11. Dupis NP, Kusumoto T, Robinson MF, et al: Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Artif Cells Blood Substit Immobil Biotechnol 23:423-429, 1995
12. Hall EJ: The Oxygen Effect and Reoxygenation: Radiobiology for the Radiologist (ed 4). Philadelphia, PA, J.B. Lippincott Co, 1994, pp 133-152
13. Kim CY, Tsai MH, Osmanian C, et al: Selection of human cervical epithelial cells that posses reduced apoptotic potential to low-oxygen conditions. Cancer Res 57:4200-4204, 1997
14. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91, 1996
15. Graaccia AJ: Hypoxic stress proteins: Survival of the fittest. Semin Radiat Oncol 6:46-58, 1996
16. Amellem O, Pettersen EO: Cell cycle progression in human cells following re-oxygenation after extreme hypoxia: Consequences concerning initiation of DNA synthesis. Cell Prolif 26:25-35, 1993
17. Krtolica A, Ludlow JW: Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res 56:1168-1173, 1996
18. Adams GE, Hasan NM, Joiner MC: Radiation, hypoxia and genetic stimulation: Implications for future therapies. Radiother Oncol 44:101-109, 1997
19. Danielsen T, Skoyum R, Rofstad EK: Hypoxia-induced changes in radiation sensitivity in human melanoma cells: Importance of oxygen-regulated proteins, adenylate energy charge and cell cycle distribution. Radiother Oncol 44:177-182, 1997
20. Sutherland RM, Ausserer WA, Murphy BJ, et al: Tumor hypoxia and heterogeneity: Challenges and opportunities for the future. Semin Radiat Oncol 6:59-70, 1996
21. Michael BD, Adams GE, Hewitt HB, et al: A posteffect of oxygen in irradiated bacteria: A submillisecond fast mixing study. Radiat Res 54:239-251, 1973
22. Flanders-Howard P, Alper T: The sensitivity of microorganisms to irradiation under controlled gas conditions. Radiat Res 7:518-540, 1957
23. Howard-Flanders P, Moore D: The time interval after pulsed irradiation within which injury to bacteria can be modified by dissolved oxygen. Radiat Res 9:422-437, 1958
24. Kwok TT, Sutherland RM: The radiation response of cells recovering after chronic hypoxia. Radiat Res 119:261-270, 1989
25. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10-21, 1996
26. Deschner EE, Gray H: Influence of oxygen tension on x-ray-induced chromosomal damage in ehrlich ascites tumor cells irradiated in vitro and in vivo. Radiat Res 11:115-146, 1959
27. Gatenby M, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
28. 2 tension measurements. Cancer Res 51:3316-3322, 1991
29. Hockel M, Schlenger K, Mitze M, et al: Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6:3-9, 1996
30. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects that prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
31. 2 tension measurements. Cancer Res 51:6098-6102, 1991
32. Hockel M, Vorndran B, Schlenger K, et al: Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 51:141-149, 1993
33. J Venitz, Slattum PW, Gerber M, et al: Pharmacokinetics (PK) of escalating IV doses of an allosteric hemoglobin (Hb) modifier, RSR13, in healthy volunteers. Pharm Res 13:8479, 1996 (abstr)
34. J Venitz, Gerber M, Abraham D: Pharmacological effects of escalating IV doses of an allosteric hemoglobin (Hb) modifier, RSR13, in healthy volunteers. Pharm Res 13:5115, 1996 (abstr)
35. Kavanagh BD, Pearlman AD, Schmidt-Ullrich RK, et al: Clinical experience with RSR13, a radiation-enhancing hemoglobin modifier, for recurrent and metastatic brain tumors. Presented at the Tenth International Conference on Chemical Modifiers of Cancer Treatment, January 1998
36. Taghian A, DuBois W, Budach W, et al: In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 32:199-204, 1995
37. Davis LW: Presidential address: Malignant glioma: A nemesis which requires clinical and basic investigation in radiation oncology. Int J Radiat Oncol Biol Phys 16:1355-1365, 1989
38. Teicher BA, Dupuis NP, Emi Y, et al: Increased efficacy of chemo- and radiotherapy by a hemoglobin solution in the 9L gliosarcoma. In Vivo 9:11-18, 1995
39. Watson ER, Halnan KE, Dische S, et al: Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix. Br J Radiol 51:879-887, 1978
40. Medical Research Council Working Party: Radiotherapy and hyperbaric oxygen: Report of a Medical Research Council Working Party. Lancet 2:881-884, 1978
41. Henk JM, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer: Interim report of second clinical trial. Lancet 2:104-105, 1977
42. Henk JM, Kunkler PB, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer: Final report of first controlled clinical trial. Lancet 2:101-103, 1977
43. Lustig R, McIntosh-Lowe N, Rose C, et al: Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck. Int J Radiat Oncol Biol Phys 16:1587-1593, 1989
44. Evans RG, Kimler BF, Morantz RA, et al: Lack of complications in long-term survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for high-grade brain tumors. Int J Radiat Oncol Biol Phys 26:649-652, 1993